GlobeImmune, Inc.
GBIMOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$575
P/E Ratio—
52W High$0.0005
52W Low$0.000001
GlobeImmune, Inc. (GBIM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GBIM · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2016Report Date: May 12, 2016EPS Actual
-$0.15
Revenue
$0.00B
Fiscal Period
Q2 FY2016
FY ends December
Report Date
May 12, 2016
After Market Close
GBIM reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2016 | May 12, 2016 | — | -$0.15 | — | $0.00B | — | — |
| — Q1 FY2016 | Mar 16, 2016 | — | -$0.14 | — | $0.00B | — | — |
| — Q4 FY2015 | Nov 13, 2015 | — | -$0.13 | — | $0.00B | — | — |
| — Q3 FY2015 | Aug 14, 2015 | — | -$0.23 | — | $0.00B | — | — |
| — Q2 FY2015 | May 14, 2015 | — | -$0.27 | — | $0.00B | — | — |
| — Q4 FY2014 | Dec 31, 2014 | — | -$0.30 | — | $0.00B | — | — |
| — Q4 FY2014 | Nov 12, 2014 | — | -$0.64 | — | $0.00B | — | — |
| — Q2 FY2014 | Jun 30, 2014 | — | -$1.04 | — | $0.00B | — | — |
Q2 FY2016
May 12, 2016
EPS Actual
-$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2016
Mar 16, 2016
EPS Actual
-$0.14
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2015
Nov 13, 2015
EPS Actual
-$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2015
Aug 14, 2015
EPS Actual
-$0.23
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2015
May 14, 2015
EPS Actual
-$0.27
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2014
Dec 31, 2014
EPS Actual
-$0.30
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2014
Nov 12, 2014
EPS Actual
-$0.64
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2014
Jun 30, 2014
EPS Actual
-$1.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
No analyst estimates available for GBIM.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2016 | May 12, 2016 | — | $1.96 | $1.18 | -39.80% |
| — Q1 FY2016 | Mar 16, 2016 | — | $2.20 | $1.89 | -14.09% |
| — Q4 FY2015 | Nov 13, 2015 | — | $2.43 | $2.21 | -9.05% |
| — Q3 FY2015 | Aug 14, 2015 | — | $2.42 | $2.48 | +2.48% |
| — Q2 FY2015 | May 14, 2015 | — | $7.40 | $7.68 | +3.78% |
| — Q4 FY2014 | Dec 31, 2014 | — | $7.28 | $7.59 | +4.26% |
| — Q4 FY2014 | Nov 12, 2014 | — | $6.50 | $6.45 | -0.77% |
| — Q2 FY2014 | Jun 30, 2014 | — | No price data | $11.05 | — |
Q2 FY2016-39.80%
Report Date
May 12, 2016
EPS Beat/Miss
—
Price Before
$1.96
Price After
$1.18
Q1 FY2016-14.09%
Report Date
Mar 16, 2016
EPS Beat/Miss
—
Price Before
$2.20
Price After
$1.89
Q4 FY2015-9.05%
Report Date
Nov 13, 2015
EPS Beat/Miss
—
Price Before
$2.43
Price After
$2.21
Q3 FY2015+2.48%
Report Date
Aug 14, 2015
EPS Beat/Miss
—
Price Before
$2.42
Price After
$2.48
Q2 FY2015+3.78%
Report Date
May 14, 2015
EPS Beat/Miss
—
Price Before
$7.40
Price After
$7.68
Q4 FY2014+4.26%
Report Date
Dec 31, 2014
EPS Beat/Miss
—
Price Before
$7.28
Price After
$7.59
Q4 FY2014-0.77%
Report Date
Nov 12, 2014
EPS Beat/Miss
—
Price Before
$6.50
Price After
$6.45
Q2 FY2014—
Report Date
Jun 30, 2014
EPS Beat/Miss
—
Price Before
—
Price After
$11.05
Beat Rate0 / 8 quarters
Largest Move-39.80% (Q2 FY2016)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GBIM ends December
GlobeImmune, Inc. (GBIM) most recently reported earnings on May 12, 2016 for Q2 FY2016, posting EPS of $-0.15 (in line with the analyst consensus of —). The next GBIM earnings date is expected around September 1, 2026.
Each quarter, investors track GBIM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GBIM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GBIM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GBIM earnings · 4 questionsGlobeImmune, Inc.'s next earnings report is expected around September 1, 2026. GBIM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GBIM historically reports after market close (AMC).
GBIM earnings datewhen is GBIM earningsGBIM next earnings datewhen does GBIM report earningsGBIM earnings calendar
▸ Source: FMP · GlobeImmune, Inc. SEC filings · US GAAP · GlobeImmune, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026